Nordea Investment Management AB Sells 1,600,906 Shares of IQVIA Holdings Inc. $IQV

Nordea Investment Management AB lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 69.2% in the fourth quarter, Holdings Channel reports. The fund owned 713,313 shares of the medical research company’s stock after selling 1,600,906 shares during the quarter. Nordea Investment Management AB’s holdings in IQVIA were worth $161,508,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Alliancebernstein L.P. grew its stake in shares of IQVIA by 1.2% during the 3rd quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock valued at $683,323,000 after purchasing an additional 41,643 shares during the period. Boston Partners bought a new position in shares of IQVIA in the 3rd quarter worth approximately $676,698,000. Artisan Partners Limited Partnership boosted its holdings in shares of IQVIA by 4.9% in the third quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock worth $652,246,000 after buying an additional 161,085 shares during the last quarter. JPMorgan Chase & Co. grew its position in IQVIA by 22.8% during the second quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after buying an additional 581,157 shares during the period. Finally, Invesco Ltd. grew its position in IQVIA by 15.3% during the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock valued at $526,891,000 after buying an additional 367,204 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of NYSE IQV opened at $165.91 on Monday. The firm has a fifty day moving average price of $194.13 and a 200-day moving average price of $206.19. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The stock has a market cap of $28.16 billion, a PE ratio of 21.11, a price-to-earnings-growth ratio of 1.60 and a beta of 1.40. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. IQVIA’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

IQV has been the topic of several recent research reports. Evercore reiterated an “outperform” rating and issued a $225.00 price target on shares of IQVIA in a research report on Thursday, February 5th. BMO Capital Markets set a $250.00 price objective on shares of IQVIA in a research report on Friday, February 6th. Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a report on Friday, March 6th. UBS Group lowered their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Finally, Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, IQVIA presently has a consensus rating of “Buy” and an average price target of $229.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.